16.04.2023, 2606 Zeichen

Marinomed: Science-based biotech company Marinomed Biotech AG, listed on the Vienna Stock Exchange, announced further positive results from its clinical study on the anti-allergic properties of its Carragelose nasal spray. The open-label, cross-over, randomized clinical trial conducted at the Vienna Challenge Chamber showed that the nasal spray can significantly decrease the symptoms of allergic rhinitis (hay fever) in patients challenged with their respective allergen. These results show that Carragelose exerts a barrier function that is not only effective in shielding the nasal mucosa from respiratory viruses, but also from pollen. This is particularly important, as patients suffering from allergic rhinitis are also sensitive to viral respiratory infections as these may worsen the underlying allergic disorder.
Marinomed Biotech: weekly performance: 2.77%

Wolford: With sales of 125.5 million Euro for the reporting period January to December 2022, bodywear group Wolford AG beat the previous year (January to December 2021) by 16.2 million Euro (+ 15%). As anticipated in the H1 Results, EBIT (operating result before financial and tax expenses) did not improve and Wolford AG closed 2022 at -28.6 million Euro. The positive sales growth is a result of increased investments in effective marketing activities, on-trend designer collaborations, as well as the impact of Wolford‘s new focused and elevated product proposition.
Wolford: weekly performance: -0.95%

Frequentis: Revenues of Frequentis, a global supplier of communication and information systems for control centres with safety-critical tasks, rose 15.7% to EUR 386.0 million. Looking at the regional split, Europe accounted for 65%, the Americas for 16%, Asia for 12%, and Australia/Pacific/Africa for 7%. Demand for Frequentis products remains high around the world. This is evidenced by order intake, which rose 21.5% to EUR 404.8 million in 2022. Orders on hand increased to EUR 522.0 million, a rise of 11.6%. The operating business was still partially held back by the COVID-19 pandemic, which subsided in 2022. The outbreak of war in Ukraine in February 2022 indirectly impacted the Frequentis Group through higher inflation (initially for electricity, gas, and fuels). Inflation then filtered through to the cost of goods sourced from suppliers, salary rises, and thus earnings. EBIT was EUR 25.0 million and the EBIT margin was 6.5%. The company registered new orders worth more than EUR 400 million.
Frequentis: weekly performance: -0.96%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (12/04/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #790: ATX schwächer, FMA kommuniziert Rekordstrafe, EVN heute 35 Jahre an der Börse, Socgen Day in Wien

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, voestalpine, Warimpex, Immofinanz, CA Immo, Addiko Bank, Andritz, Frequentis, AT&S, Zumtobel, OMV, FACC, Uniqa, Strabag, Austriacard Holdings AG, Amag, Cleen Energy, DO&CO, Marinomed Biotech, UBM, Wolford, Oberbank AG Stamm, Kapsch TrafficCom, Agrana, Erste Group, EVN, Flughafen Wien, Palfinger, Österreichische Post, S Immo, Telekom Austria.

---